Pharmanutra SpA
F:761
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Pharmanutra SpA
F:761
|
IT |
|
A
|
Ashmore Group PLC
OTC:AJMPF
|
UK |
|
Palamina Corp
XTSX:PA
|
CA |
|
P
|
Premier Development & Investment Inc
OTC:PDIV
|
US |
|
Rosslyn Data Technologies PLC
F:7IU
|
UK |
Wall St Price Targets
Price Targets Summary
Pharmanutra SpA
According to Wall Street analysts, the average 1-year price target for Pharmanutra SpA is 54.75 EUR with a low forecast of 52.87 EUR and a high forecast of 58.55 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is Pharmanutra SpA's stock price target?
Price Target
54.75
EUR
According to Wall Street analysts, the average 1-year price target for Pharmanutra SpA is 54.75 EUR with a low forecast of 52.87 EUR and a high forecast of 58.55 EUR.
What is the Revenue forecast for Pharmanutra SpA?
Projected CAGR
9%
Over the last 9 years, the compound annual growth rate for Revenue has been 17%. The projected CAGR for the next 8 years is 9%.
What is the Gross Profit forecast for Pharmanutra SpA?
Projected CAGR
13%
Over the last 9 years, the compound annual growth rate for Gross Profit has been 17%. The projected CAGR for the next 2 years is 13%.
What is the Operating Income forecast for Pharmanutra SpA?
Projected CAGR
9%
Over the last 9 years, the compound annual growth rate for Operating Income has been 19%. The projected CAGR for the next 8 years is 9%.
What is the Pre-Tax Income forecast for Pharmanutra SpA?
Projected CAGR
18%
Over the last 9 years, the compound annual growth rate for Pre-Tax Income has been 20%. The projected CAGR for the next 3 years is 18%.
What is the Net Income forecast for Pharmanutra SpA?
Projected CAGR
19%
Over the last 9 years, the compound annual growth rate for Net Income has been 20%. The projected CAGR for the next 3 years is 19%.
